Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Completed · Phase 2/Phase 3
Conditions studied: Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome, Kidney Diseases, Gastrointestinal Diseases
In brief
The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical improvement/worsening of both renal and gastrointestinal functions.
Key facts
- Study ID
- NCT00035334
- Run by
- Bellus Health Inc. - a GSK company
- People needed
- 150
- Starts
- 2001-10-01
- Expected to finish
- 2004-12-01
- Last updated by the study team
- 2006-02-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Indiana University School of Medicine, Department of Pathology and Laboratory Medicine, — Indianapolis, Indiana, United States
- Boston Medical Center, Renal Division — Boston, Massachusetts, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Mount Sinai Medical Center — New York, New York, United States
- Rheumatism Foundation Hospital — Heinola, Finland
- Centre Hospitalier du Mans, Service de Rhumatologie — Le Mans, France
- Hôpital Claude Huriez, Service de médecine Interne, Clinique Médicale A — Lille, France
- Hôpital Cochin, Centre de Recherche et d'Explorations Fonctionnelles — Paris, France
- Bnai Zion Medical Center — Haifa, Israel
- Heller Institute of Medical Research, Sheba Medical Center — Tel Litwinsky, Israel
- Italian Group for Systemic Amyloidosis, Biotechnology Research Laboratories, IRCCS Policlinico San Matteo, Internal Medicine and Medical Oncology — Pavia, Italy
- Vilnius University Hospital — Vilnius, Lithuania
- University Hospital Groningen, Department of Medicine, Division of Rheumatology — Groningen, Netherlands
- Instytut Reumatologiczny — Warsaw, Poland
- Okregowy Szpital Kolejowy, Zaklad Reumatologii — Wroclaw, Poland
- Institute of Rheumatology RAMS — Moscow, Russia
- Regional Hospital No. 1 — Yekaterinburg, Russia
- Hospital Universitario Germans Trias I Pujol, Servicio de Reumatologia — Badalona, Spain
- Hospital Clinic I Provincial de Barcelona, Jefe del Departamento de Reumatologia — Barcelona, Spain
- Ciutad Sanitària y Universitària de Bellvitge, Servicio de Reumatologia, Hospitalet de Llobregat — Llobregat, Spain
- Hospital Clinico San Carlos de Madrid, Servicio de Reumatologia — Madrid, Spain
- Cerrehpasa Tip Fakultesi — Askaray, Istanbul, Turkey, Turkey (Türkiye)
- Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology — Istanbul, Turkey (Türkiye)
- Marmara University Medical School Hospital, Department of Rheumatology — Uskudar, Altunizade, Istanbul, Turkey (Türkiye)
- Royal Free and University College Medical School, Department of Medicine, National Amyloidosis Centre — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.